Alloy Therapeutics
Biotechnology ecosystem company providing integrated discovery technologies, services, and platform access across multiple biologic modalities (antibodies, bispecifics, TCRs/TCR mimics, genetic medicines, peptides, and cell therapies). Operates humanized transgenic mouse discovery platforms, antigen generation and QC, high-throughput wet-lab and analytical workflows, and AI/ML-driven sequence design and repertoire mining. Offers platform licensing, subscription access models, venture-studio and joint-venture support, and regional centers of excellence for iPSC-derived cell therapy development.
Industries
Nr. of Employees
small (1-50)
Services
Antibody discovery services (monoclonal)
End-to-end monoclonal discovery including in vivo immunization, B-cell recovery, deep sequencing, AI/ML repertoire mining, sequence prioritization, and functional characterization for therapeutic antibody lead identification.
Bispecific discovery and engineering
Modular discovery of monoclonal arms, format engineering, high-throughput expression of bispecific panels, and customized functional screening cascades to deliver rank-ordered bispecific leads.
Antibody optimization (computational design + high-throughput testing)
AI/ML-guided in silico design coupled with high-throughput expression and characterization to optimize affinity, specificity, developability, immunogenicity, and Fc properties.
TCR/TCR-mimic discovery services
Comprehensive discovery and engineering services for engineered TCRs and TCR-mimic proteins, including peptide–MHC complex production, specificity testing, affinity maturation, and preclinical characterization.
Genetic medicines (antisense) discovery
Design and discovery of antisense oligonucleotide therapeutics using engineered oligonucleotide chemistries and formats intended to improve potency, safety, and delivery (including applications for CNS targets).
Cell therapy platform development (iPSC-derived CAR-T/NK)
Development and scale-up support for iPSC-derived off-the-shelf cell therapy platforms, including CAR and TCR engineering, hypoimmune features, and platform enhancement toward clinical translation.
Antibody discovery services (monoclonal)
End-to-end monoclonal discovery including in vivo immunization, B-cell recovery, deep sequencing, AI/ML repertoire mining, sequence prioritization, and functional characterization for therapeutic antibody lead identification.
Bispecific discovery and engineering
Modular discovery of monoclonal arms, format engineering, high-throughput expression of bispecific panels, and customized functional screening cascades to deliver rank-ordered bispecific leads.
Antibody optimization (computational design + high-throughput testing)
AI/ML-guided in silico design coupled with high-throughput expression and characterization to optimize affinity, specificity, developability, immunogenicity, and Fc properties.
TCR/TCR-mimic discovery services
Comprehensive discovery and engineering services for engineered TCRs and TCR-mimic proteins, including peptide–MHC complex production, specificity testing, affinity maturation, and preclinical characterization.
Genetic medicines (antisense) discovery
Design and discovery of antisense oligonucleotide therapeutics using engineered oligonucleotide chemistries and formats intended to improve potency, safety, and delivery (including applications for CNS targets).
Cell therapy platform development (iPSC-derived CAR-T/NK)
Development and scale-up support for iPSC-derived off-the-shelf cell therapy platforms, including CAR and TCR engineering, hypoimmune features, and platform enhancement toward clinical translation.
Expertise Areas
- In vivo antibody discovery using humanized transgenic models
- Antigen generation and tailored immunization strategies
- B-cell recovery, repertoire sequencing, and informatics
- AI/ML-driven protein and antibody design
Key Technologies
- Humanized transgenic mouse discovery platforms
- Antigen production and QC for protein, cell-based, and genetic formats
- LNP mRNA and DNA immunization methods
- RIMMS and tolerance‑breaking immunization protocols